MX2020006040A - Intermedios para derivados de piperidina opticamente activos y procedimientos de preparacion de los mismos. - Google Patents

Intermedios para derivados de piperidina opticamente activos y procedimientos de preparacion de los mismos.

Info

Publication number
MX2020006040A
MX2020006040A MX2020006040A MX2020006040A MX2020006040A MX 2020006040 A MX2020006040 A MX 2020006040A MX 2020006040 A MX2020006040 A MX 2020006040A MX 2020006040 A MX2020006040 A MX 2020006040A MX 2020006040 A MX2020006040 A MX 2020006040A
Authority
MX
Mexico
Prior art keywords
optically active
intermediates
preparation methods
piperidine derivatives
active piperidine
Prior art date
Application number
MX2020006040A
Other languages
English (en)
Inventor
Hyuk Woo Lee
Jae Hong Kweon
Kwang Do Choi
Dong Hyun Ko
Seung Pyeong Heo
Eun Sun Kim
Chae Young Ryu
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of MX2020006040A publication Critical patent/MX2020006040A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/18Carbon
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44Palladium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Un procedimiento de preparación de acuerdo con la presente invención hace posible producir industrialmente grandes cantidades de 3-metil-4-oxopiperidin-1- carboxilato de terc-butilo ópticamente puro de alta pureza con gran rendimiento mediante el uso de reactivos y disolventes disponibles comercialmente. Además, el uso de intermedios novedosos de acuerdo con la presente invención hace posible producir 3-metil-4-oxopiperidin-1-carboxilato de terc-butilo ópticamente activo de alta pureza con gran rendimiento.
MX2020006040A 2017-12-11 2018-12-07 Intermedios para derivados de piperidina opticamente activos y procedimientos de preparacion de los mismos. MX2020006040A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170169227A KR102037494B1 (ko) 2017-12-11 2017-12-11 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
PCT/KR2018/015559 WO2019117550A1 (en) 2017-12-11 2018-12-07 Intermediates for optically active piperidine derivatives and preparation methods thereof

Publications (1)

Publication Number Publication Date
MX2020006040A true MX2020006040A (es) 2020-10-12

Family

ID=66819511

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006040A MX2020006040A (es) 2017-12-11 2018-12-07 Intermedios para derivados de piperidina opticamente activos y procedimientos de preparacion de los mismos.

Country Status (11)

Country Link
US (2) US11254641B2 (es)
EP (1) EP3724162B1 (es)
JP (1) JP6966656B2 (es)
KR (1) KR102037494B1 (es)
CN (1) CN111587240B (es)
AU (1) AU2018385820B2 (es)
CA (1) CA3085427C (es)
ES (1) ES2960509T3 (es)
MX (1) MX2020006040A (es)
RU (1) RU2752477C1 (es)
WO (1) WO2019117550A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
KR102786122B1 (ko) * 2019-09-23 2025-03-24 주식회사 엘지화학 화합물의 제조방법
CN114213316B (zh) * 2021-12-29 2024-04-02 苏州诚和医药化学有限公司 一种旋光哌啶衍生物的中间体的生产工艺
CN115010652A (zh) * 2022-07-14 2022-09-06 苏州诚和医药化学有限公司 一种哌啶类衍生物中间体的合成工艺

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU606310A1 (ru) 1976-10-29 1984-05-23 Московский государственный университет им.М.В.Ломоносова Способ получени (+) и (-)-формы оптически активного транс-2,5-диметилпиперидона-4
FR2717803B1 (fr) * 1994-03-25 1996-06-21 Meram Lab Dérivés substitués d'hétérocycles azotés et leurs isomères, actifs sur le système nerveux central, procédé d'obtention et compositions pharmaceutiques les contenant.
JP2003506369A (ja) 1999-07-29 2003-02-18 イーライ・リリー・アンド・カンパニー セロトニン作動性のベンゾフラン
EP1558599A4 (en) 2002-10-30 2007-06-27 Merck & Co Inc HETEROARYLPIPERIDINE MODULATORS DERCHEMOKIN RECEPTORACTIVITY
US7378525B2 (en) 2002-12-23 2008-05-27 Millennium Pharmaceuticals, Inc. CCR8 inhibitors
MXPA05011223A (es) 2003-04-18 2006-01-26 Lilly Co Eli Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
DE602004019118D1 (de) 2003-09-17 2009-03-05 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
US20120041225A1 (en) * 2006-02-03 2012-02-16 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
GB0706165D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
EP2173713B1 (en) * 2007-07-24 2016-02-17 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
WO2009106534A1 (en) 2008-02-26 2009-09-03 H. Lundbeck A/S Novel heterocyclic carboxamides as m1 agonists
US20100279997A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Analgesic that binds filamin a
KR101146009B1 (ko) * 2009-10-01 2012-05-15 동인화학 주식회사 광학 분리에 의한 활성 피페리딘 화합물의 제조방법
US8642622B2 (en) * 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
EP2742047B1 (en) 2011-08-10 2021-05-12 Janssen Sciences Ireland Unlimited Company Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
US9409884B2 (en) 2012-02-01 2016-08-09 Rigel Pharmaceuticals, Inc. 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US9296760B2 (en) 2012-08-10 2016-03-29 Janssen Sciences Ireland Uc Antibacterial compounds
JP2018510131A (ja) 2015-01-30 2018-04-12 ファイザー・インク Rorc2のスルホンアミド置換インドールモジュレーターおよびその使用方法
US10336748B2 (en) 2015-01-30 2019-07-02 Pfizer Inc. Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법

Also Published As

Publication number Publication date
AU2018385820B2 (en) 2021-08-12
KR102037494B1 (ko) 2019-10-28
CA3085427C (en) 2023-03-14
WO2019117550A1 (en) 2019-06-20
US20220127230A1 (en) 2022-04-28
ES2960509T3 (es) 2024-03-05
AU2018385820A1 (en) 2020-07-30
BR112020011630A2 (pt) 2020-11-17
RU2752477C1 (ru) 2021-07-28
EP3724162C0 (en) 2023-10-11
US20210107873A1 (en) 2021-04-15
CA3085427A1 (en) 2019-06-20
EP3724162B1 (en) 2023-10-11
KR20190068946A (ko) 2019-06-19
CN111587240B (zh) 2023-09-01
CN111587240A (zh) 2020-08-25
US11254641B2 (en) 2022-02-22
EP3724162A1 (en) 2020-10-21
US11780810B2 (en) 2023-10-10
JP2021505682A (ja) 2021-02-18
JP6966656B2 (ja) 2021-11-17
EP3724162A4 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
JOP20160185B1 (ar) طريقة لتحضير (4s)-4-(4- سيانو-2- ميثوكسي فنيل)-5- إيثوكسي-8،2-داي ميثيل-4،1-داي هيدرو-6،1- نافثيريدين-3- كربوكساميد واسترجاع (4s)-4-(4- سيانو-2- ميثوكسي فنيل)-5- إيثوكسي-8،2- داي ميثيل-4،1- داي هيدرو-6،1- نافثيريدين-3- كربوكساميد بواسطة طرق كهروكيميائية
PH12019502286A1 (en) Process for preparing an optically active pyrimidinium compounds
PH12019502386A1 (en) Process for preparing s-containing pyrimidinium compounds
MY172391A (en) Processes for preparing dihydropyrimidine derivatives and intermediates thereof
SG10201809312QA (en) Nucleic acid synthesis techniques
IN2014CH00247A (es)
PH12018500151A1 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
MX2015015188A (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
WO2015008218A3 (en) Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant
WO2018029711A3 (en) Process for the preparation of venetoclax
PH12018501642B1 (en) Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof
MX2016011367A (es) Microorganismo recombinante que expresa analogos de avermectina y uso de los mismos.
MX2019001465A (es) Metodo de produccion de cetoenoles ciclicos sustituidos con espirocetales.
WO2016012445A3 (en) Process for the purification of poliovirus from cell cultures
MX2014014138A (es) Procedimiento nuevo para la preparacion de acido 2-ciclopentil-6-metoxi-isonicotinico.
MX2018004009A (es) Proceso para la recuperacion de una mezcla que comprende un derivado de acido (tio) fosforico.
PH12016501704B1 (en) Method for producing 2-acyliminopyridine derivative
MX2017012027A (es) Desaminacion de nucleosidos organofosforados.
NZ727773A (en) Metal-catalyzed asymmetric 1,4-conjugate addition of vinylboron compounds to 2-substituted-4-oxy- cyclopent-2-en-1-ones yielding prostaglandins and prostaglandin analogs
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
MX381604B (es) Proceso para preparar de temozolomida y un intermediario.
WO2017093866A3 (en) An improved process for the preparation of indigo carmine
WO2016084100A3 (en) Novel and efficient method for large scale synthesis of romidepsin
MX379825B (es) Nuevas formas cristalinas de la sal de monosodio del foramsulfuron.
IN2014MU00486A (es)